Image

Global Postmenopausal Vaginal Atrophy (PVA) Drugs Market – Industry Trends and Forecast to 2029

Pharmaceutical

Image

Global Postmenopausal Vaginal Atrophy (PVA) Drugs Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Nov 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Postmenopausal Vaginal Atrophy (PVA) Drugs Market – Industry Trends and Forecast to 2029

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period 2021–2029
Diagram Market Size (Base Year) USD 2.00 USD Billion
Diagram Market Size (Forecast Year) USD 3.57 USD Billion
Diagram CAGR %

Major Markets Players

  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

Global Postmenopausal Vaginal Atrophy (PVA) Drugs Market, By Drugs (Topical Estrogen, Oral Estrogen, Others), Product (Creams, Pessaries, Tablets, Gels, Solutions, Inserts, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.

Postmenopausal Vaginal Atrophy (PVA) Drugs Market

Postmenopausal Vaginal Atrophy (PVA) Drugs Market Analysis and Size

The global postmenopausal vaginal atrophy (PVA) drugs market is expected to witness significant growth during the forecast period. The common symptoms associated with this condition include irritation, burning sensation, redness, and dyspareunia. Several branded and generic drugs are available in the market for the treatment of postmenopausal vaginal atrophy. The development of top non-estrogen-based drugs has also helped the market gain pace in the recent years. In addition to this, the enhancement of the healthcare reforms for meeting the requirements to treat vaginal atrophy is also a major factor boosting the development of the market.

Data Bridge Market Research analyses a growth rate in global postmenopausal vaginal atrophy (PVA) drugs market in the forecast period 2022-2029. The expected CAGR of global postmenopausal vaginal atrophy (PVA) drugs market is tend to be around 7.50% in the mentioned forecast period. The market was valued at USD 2 billion in 2021, and it would grow upto USD 3.57 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Postmenopausal Vaginal Atrophy (PVA) Drugs Market Scope and Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Drugs (Topical Estrogen, Oral Estrogen, Others), Product (Creams, Pessaries, Tablets, Gels, Solutions, Inserts, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Pfizer Inc (U.S.), Mylan N.V. (U.S.), Novartis AG (Switzerland), Hikma Pharmaceuticals plc (U.K.), Aurobindo Pharma (India), AbbVie Inc. (Ireland), Melinta Therapeutics, Inc (U.S.), Bristol-Myers Squibb Company (U.S.), GSK plc. (U.K.), Bayer AG (Germany), Lupin (India), Perrigo Company plc (U.S.), Bionovo, Inc. (Saudi Arabia), TherapeuticsMD, Inc. (U.S.), Endoceutics, Inc (Canada)

Market Opportunities

  • Increased Awareness of the Disease
  • Increasing Demand for Retail Pharmacies

Market Definition

Postmenopausal vaginal atrophy (PVA) is the type of condition of vaginal wall thinning the reduced level of estrogen causes that. The changes in the genitourinary tract arising from a hypoestrogenic state includes decreased vaginal vascularization, reduced vaginal lubrication, thinning of the vaginal epithelium. The pH level continuously increases and loss of lactobacilli microflora allows opportunistic colonization by pathogenic bacteria can produce infection.

Global Postmenopausal Vaginal Atrophy (PVA) Drugs Market Dynamics

Drivers

  • Prevalence of Postmenopausal Vaginal Atrophy

The increasing incidence of postmenopausal vaginal atrophy boosts the demand for treatment methods. The most prevalent symptom is vaginal dryness which affects 60% of women in the postmenopausal period. These symptoms can generally lead to sexual dysfunction and subsequently to reduced quality of life.

  • Growing Healthcare Plans

Numerous established healthcare infrastructures, as well as the increased frequency of disease and the occurrence of significant manufacturers, are the primary factors contributing to the market share. For instance, The Affordable Care Act has increased the number of insured women and has been a boosting factor in the treatment-seeking behavior of people with this condition. Furthermore, this law provides many U.S. citizens with better health security by putting in place comprehensive health insurance reforms that have reduced healthcare costs and expanded coverage. Consequently, the introduction of beneficial healthcare plans in the US will prompt more women to seek treatment, thereby helping in the growth of this market during the forecast period.

Opportunities

  • Increased Awareness of the Disease

The rising awareness among the population about this kind of disease results in the market's growth. The growing awareness about the benefits of postmenopausal vaginal atrophy drugs encourages people to opt for this treatment. Furthermore, in developed countries such as the US, women can openly discuss their symptoms with their physician, which creates awareness and helps in early diagnosis, thus encouraging this market growth.

  • Increasing Demand for Retail Pharmacies

The rise in the number of postmenopausal vaginal atrophy drugs delivered through retail pharmacies and the surge in the number of retail pharmacies in highly advanced countries create much opportunities for the market growth. Additionally, patients choose retail pharmacies for purchasing drugs, as these are easily available.

 Restraints/Challenges

  • Lack of Awareness about the infection

The lack of awareness about these infections could curb the growth of the global postmenopausal vaginal atrophy drugs market over a forecast period. Not much attention about the infection leads to improper treatment thus restraining the market growth.

  • High Cost

The huge expenditure associated with these agents surely hamper the market growth. Several antifungal, antiviral, antibacterial drugs are facing an increasing hike and thus is hampering the market growth.

This global postmenopausal vaginal atrophy (PVA) drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global postmenopausal vaginal atrophy (PVA) drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Postmenopausal Vaginal Atrophy (PVA) Drugs Market    

The COVID-19 pandemic has hindered the development, production, and supply of drugs and other healthcare products and affected many companies' growth of healthcare businesses worldwide. However, in the post-pandmeic era, the market is projected to grow because of an increase in R&D initiatives for exact diagnosis. Numerous government and non-government bodies, including the European Institute of Women's Health (EIWH) and the World Health Organization, have launched multiple public awareness campaigns about women's health.Thus, COVID-19 left a major imapact on the global postmenopausal vaginal atrophy (PVA) drugs market.

Global Postmenopausal Vaginal Atrophy (PVA) Drugs Market Scope

The global postmenopausal vaginal atrophy (PVA) drugs market is segmented on the basis of drugs, product, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drugs

  • Topical Estrogen
  • Oral Estrogen
  • Others

Product

  • Creams
  • Pessaries
  • Tablets
  • Gels
  • Solutions
  • Inserts
  • Others

End User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Postmenopausal Vaginal Atrophy (PVA) Drugs Market Regional Analysis/Insights

The global postmenopausal vaginal atrophy (PVA) drugs market is analyzed and market size insights and trends are provided by drugs, product, distribution channel and end-user as referenced above.

The major countries covered in the global postmenopausal vaginal atrophy (PVA) drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing a positive growth for global postmenopausal vaginal atrophy (PVA) drugs market throughout the forecasted period because of the increasing initiatives taken by the government and pharmaceutical organizations to spread awareness and increased occurrence of vaginal infection in women.

North America dominates the market because of the increasing initiatives taken by the pharmaceutical organizations to generate novel formulation and well-spread awareness of anti-infectives among end-users. 

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Global Postmenopausal Vaginal Atrophy (PVA) Drugs Market Share Analysis

The global postmenopausal vaginal atrophy (PVA) drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related global postmenopausal vaginal atrophy (PVA) drugs market.

Key players operating in the global postmenopausal vaginal atrophy (PVA) drugs market include:

  • Pfizer Inc (U.S.)
  • Mylan N.V. (U.S.)
  • Novartis AG (Switzerland)
  • Hikma Pharmaceuticals plc (U.K.)
  • Aurobindo Pharma (India)
  • AbbVie Inc. (Ireland)
  • Melinta Therapeutics, Inc (U.S.)
  • Bristol-Myers Squibb Company (U.S.)
  • GSK plc. (U.K.)
  • Bayer AG (Germany)
  • Lupin (India)
  • Perrigo Company plc (U.S.)
  • Bionovo, Inc. (Saudi Arabia)
  • TherapeuticsMD, Inc. (U.S.)
  • Endoceutics, Inc (Canada)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

FREQUENTLY ASK QUESTIONS

The postmenopausal vaginal atrophy (PVA) drugs market size will be worth USD 3.57 billion by 2029.
The growth rate of the postmenopausal vaginal atrophy (PVA) drugs market is 7.50% in the forecast period by 2029.
Major companies in the postmenopausal vaginal atrophy (PVA) drugs market are Pfizer Inc (U.S.), Mylan N.V. (U.S.), Novartis AG (Switzerland), Hikma Pharmaceuticals plc (U.K.), Aurobindo Pharma (India), AbbVie Inc. (Ireland), Melinta Therapeutics, Inc (U.S.), Bristol-Myers Squibb Company (U.S.), GSK plc. (U.K.), Bayer AG (Germany), Lupin (India), Perrigo Company plc (U.S.), Bionovo, Inc. (Saudi Arabia), TherapeuticsMD, Inc. (U.S.), Endoceutics, Inc (Canada).
Drugs, products, distribution channels, and end-user are the factors on which the postmenopausal vaginal atrophy (PVA) drugs market research is based.
The increasing incidence of postmenopausal vaginal atrophy & numerous established healthcare infrastructures, as well as the increased frequency of disease and the occurrence of significant manufacturers, are the growth drivers of the postmenopausal vaginal atrophy (PVA) drugs market.
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials